Altimmune Inc Share Price Nasdaq
Equities
US02155H1014
Biotechnology & Medical Research
Sales 2024 * | 31.25M 2.61B | Sales 2025 * | 25M 2.09B | Capitalization | 525M 43.9B |
---|---|---|---|---|---|
Net income 2024 * | -59M -4.93B | Net income 2025 * | -142M -11.86B | EV / Sales 2024 * | 14.8 x |
Net cash position 2024 * | 63.88M 5.34B | Net cash position 2025 * | 257M 21.44B | EV / Sales 2025 * | 10.7 x |
P/E ratio 2024 * |
-8.8
x | P/E ratio 2025 * |
-5.88
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
Latest transcript on Altimmune Inc
Managers | Title | Age | Since |
---|---|---|---|
Vipin K. Garg
CEO | Chief Executive Officer | 67 | 30/18/30 |
Director of Finance/CFO | 66 | 31/21/31 | |
Anthony Blandin
CMP | Compliance Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchel Sayare
CHM | Chairman | 76 | 01/10/01 |
Mack Gill
BRD | Director/Board Member | 72 | 01/04/01 |
Philip Hodges
BRD | Director/Board Member | 56 | 01/03/01 |
1st Jan change | Capi. | |
---|---|---|
+16.45% | 122B | |
+21.96% | 116B | |
+25.50% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-15.89% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |